As epigenetics involvement in AD pathogenesis is increasingly illustrated[12], compounds with PKC activation and HDAC inhibition properties may offer a new approach to therapies that exhibit disease-modifying effects in the treatment of AD, as opposed to symptomatic relief only[13]. This evidence concerns the gene HDAC9 and Alzheimer disease.